Coronavirus: Nigeria to continue clinical trial of hydroxychloroquine despite WHO suspension

The National Agency for Food and Drug Administration and Control, NAFDAC, has said that it will continue the clinical trial of hydroxychloroquine despite the World Health Organization, WHO, announcing the suspension.

The Director-General of NAFDAC, Professor Mojisola Adeyeye, disclosed this while speaking on TVC's Your View on Tuesday.

Adeyeye also revealed that the clinical trial could be concluded within four months if medical doctors, research scientists, pharmacists and herbal experts work together.

"There is data to prove that hydroxychloroquine worked for many covid-19 patients. Therefore, we would continue our own clinical trails in Nigeria", the NAFDAC DG said.

"Hydroxychloroquine has been proved to work at the mild stage. So the potency depends on the severity of the disease in the patient's body.

"If Medical doctors, research scientists, pharmacists, herbal experts work together, we should conclude the clinical trial in 3-4 months. The narrative might change afterwards but for now, we believe in hydroxychloroquine."

On why African countries haven't recorded as much cases as projected by WHO, Adeyeye said, "It could be our weather or the vaccine we were given as kids but science would prove itself and we are working on gathering that data."